-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

623A.O2.6 623. Mantle Cell, Follicular, Waldenstrom’s, and Other Indolent B Cell Lymphomas: Clinical and Epidemiological: Novel Treatment Strategies and New Data on Old Standards for Follicular Lymphoma

Symposia: Mantle Cell, Follicular, Waldenstrom's, and Other Indolent B Cell Lymphomas: Clinical and Epidemiological Program: Oral and Poster Abstracts
Type: Oral
Hematology Disease Topics & Pathways:
Research, Clinical trials, Combination therapy, Adult, Epidemiology, Lymphomas, Non-Hodgkin lymphoma, Clinical Practice (Health Services and Quality), Bispecific Antibody Therapy, Translational Research, Drug development, Clinical Research, B Cell lymphoma, Diseases, Indolent lymphoma, Therapy sequence, Treatment Considerations, Biological therapies, Immunotherapy, Lymphoid Malignancies, Biological Processes, Molecular biology, Technology and Procedures, Study Population, Human, Measurable Residual Disease , Transplantation (Allogeneic and Autologous), Molecular testing
Saturday, December 7, 2024: 4:00 PM-5:30 PM
Marriott Grand Ballroom 11-13 (Marriott Marquis San Diego Marina)
Moderators:
Erika Haydu, MD PhD, Massachusetts General Hospital Cancer Center and Dipti Talaulikar, PhD, FRACP, FRCPA, MBBS, Australian National University
Disclosures:
Haydu: Abbvie/Genmab: Consultancy, Research Funding. Talaulikar: Antengene: Honoraria; Roche: Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding, Speakers Bureau; Janssen: Membership on an entity's Board of Directors or advisory committees, Research Funding, Speakers Bureau; Beigene: Honoraria, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Immutep: Current equity holder in publicly-traded company.

Novel treatments for WM and FL are included in the cases of high impact as well as large studies providing new insights into treatments that have been considered standards in the past
4:00 PM

Juan Pablo Alderuccio, MD1, Alvaro J Alencar, MD2, Jonathan H. Schatz, MD3, Russ Kuker, MD4*, David Sicre, PharmD, MBA5*, Georgios Pongas, MD1*, Isildinha M. Reis, PhD6*, Jay Y. Spiegel, MD, FRCPC1, Laura Medina Andara, MD7*, Lazaros J. Lekakis8*, Joseph S. Gyedu7*, Jose Sandoval-Sus, MD9, Amer M. Beitinjaneh, MD, MS10*, Michele D. Stanchina, DO, MS11, Asaad Trabolsi, MD12, Izidore S. Lossos, MD13, Joseph D. Rosenblatt, MD14*, David S. Lessen, MD7* and Craig H. Moskowitz, MD15

1Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL
2Sylvester Comprehensive Cancer Center, Division of Hematology, University of Miami, Miller School of Medicine, Miami Beach, FL
3University of Miami, Miami, FL
4Department of Radiology, Division of Nuclear Medicine, University of Miami, Miller School of Medicine, Miami, FL
5Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL
6Department of Public Health Sciences and Biostatistics and Bioinformatics Shared Resource, University of Miami Miller School of Medicine, Miami, FL
7Sylvester Comprehensive Cancer Center, Miami
8Sylvester Comprehensive Cancer Center, University of Miami Health System, Miami, FL
9Moffitt Cancer Center at Memorial Healthcare System, Pembroke Pines, FL
10Division of Transplantation and Cellular Therapy, University of Miami Hospital and Clinics, Sylvester Comprehensive Cancer Center, Miami, FL
11Sylvester Comprehensive Cancer Center, Division of Hematology, University of Miami, Miller School of Medicine, Miami, FL
12University of Miami, Sylvester Comprehensive Cancer Center, Miami, FL
13Division of Hematology, Sylvester Comprehensive Cancer Center, Miami, FL
14University of Miami Sylvester Comprehensive Cancer Center, Miami, FL
15Sylvester Comprehensive Cancer Center, University of Miami, Coral Gables, FL

4:15 PM

Noriko Fukuhara, MD, PhD1, Dai Maruyama, MD, PhD2, Kenichi Ishizawa, MD, PhD3*, Yusuke Sano, MD4*, Ryunosuke Machida5*, Shinichi Makita6*, Wataru Munakata, MD, PhD6*, Satoshi Ichikawa, MD, PhD7*, Keiko Aizawa, MD8*, Kana Miyazaki, MD, PhD9, Yoshihiro Kameoka, MD, PhD10*, Shinya Rai, MD, PhD11, Yu Yagi, MD12*, Naoki Takahashi, MD, PhD13*, Toshiki Mushino14*, Takeharu Kato, M.D., Ph.D.15*, Yuri Miyazawa, MD, PhD16*, Toko Saito, MD17*, Kazuyuki Shimada, MD, PhD18, Junya Kuroda, MD, PhD19, Hideki Uryu, MD20*, Yuko Mishima2*, Nobuyuki Takayama21, Yasuhiro Suzuki, MD, PhD22*, Toshiki Uchida, MD, PhD23*, Nobuhiko Nakamura, MD, PhD24*, Takayuki Tabayashi, MD, PhD25*, Yosuke Minami, MD, PhD26, Nobuaki Dobashi, MD, PhD27, Kunihiro Tsukasaki, MD, PhD28 and Hirokazu Nagai, MD, PhD22

1Department of Hematology, Tohoku University Graduate School of Medicine, Sendai, Japan
2Department of Hematology Oncology, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan
3Division of Hematology, Yamagata University Hospital, Yamagata, JPN
4JCOG Data Center/Operations Office, National Cancer Center Hospital, Tokyo, Japan
5Japan Clinical Oncology Group Datacenter/Operations Office, National Cancer Center, Tokyo, JPN
6Department of Hematology, National Cancer Center Hospital, Tokyo, Japan
7Department of Hematology, Tohoku University Hospital, Sendai, Japan
8Division of Hematology, Yamagata University Hospital, Yamagata, Japan
9Department of Hematology and Oncology, Mie University Graduate School of Medicine, Tsu, Japan
10Department of Hematology, Nephrology, and Rheumatology, Akita University, Akita, AKI, JPN
11Department of Hematology and Rheumatology, Kindai University Hospital, Osaka, Japan
12Department of Medical Oncology, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital, Tokyo, Japan
13Department of Hematology, International Medical Center, Saitama Medical University, Saitama, Japan
14Department of Hematology/Oncology, Wakayama Medical University, Wakayama, Japan
15Department of Hematology, Nagasaki University Hospital, Nagasaki, Japan
16Department of Hematology, Gunma University Graduate School of Medicine, Maebashi, Japan
17Department of Hematology and Cell Therapy, Aichi Cancer Center Hospital, Nagoya, JPN
18Department of Hematology and Oncology, Nagoya University Graduate School of Medicine, Nagoya, Japan
19Division of Hematology and Oncology, Department of Medicine,, Kyoto Prefectural University of Medicine, Kyoto, Japan
20The Jikei University Hospital, Minato-ku, Tokyo, Japan
21Department of Hematology, Kyorin University Faculty of Medicine, Mitaka, Tokyo, Japan
22Department of Hematology, National Hospital Organization Nagoya Medical Center, Nagoya, JPN
23Department of Hematology and Oncology, Japanese Red Cross Aichi Medical Center Nagoya Daini Hospital, Nagoya, Japan
24Department of Hematology and Infectious Disease, Gifu University Hospital, Gifu, Japan
25Department of Hematology, Saitama Medical Center, Saitama Medical University, Kawagoe, Japan
26National Cancer Center Hospital East, Kashiwa, Japan
27Division of Clinical Oncology/Hematology, The Jikei University Daisan Hospital, Tokyo, Japan
28Department of Hematology, Saitama Medical University International Medical Center, Saitama, Japan

4:30 PM

Simone Ferrero, MD1,2, Ilaria Del Giudice3*, Sara Galimberti, MD4*, Valter Gattei, MD5, Luigi Marcheselli6*, Elisa Genuardi2*, Daniela Drandi2*, Mariapia Pironti, MD2*, Irene Dogliotti, MD1*, Aurora Maria Civita2*, Irene Della Starza, PhD3,7*, Giovanni Manfredi Assanto3*, Francesca Guerrini4*, Clara Bono4*, Riccardo Bomben, PhD5*, Carola Boccomini8*, Lucia Farina9*, Jacopo Olivieri, MD10*, Luca Arcaini, MD11*, Federica Cavallo1,2*, Filippo Ballerini12*, Gloria Margiotta Casaluci, MD13*, Vittorio Ruggero Zilioli14*, Manuela Zanni, MD15*, Gerardo Musuraca, M.D., Ph.D.16*, Anna Merli17*, Benedetta Bianchi, MD18*, Silvia Bolis, MD19*, Vincenzo Pavone, MD20*, Annalisa Chiarenza21*, Annalisa Arcari22*, Catello Califano, MD23*, Samantha Pozzi, MD24*, Massimo Massaia25, Annarita Conconi26*, Tommasina Perrone, MD27*, Donato Mannina28*, Alessandro Re, MD29*, Maria Elena Nizzoli, MD30*, Dimitri Dardanis4*, Stefano Luminari30,31 and Marco Ladetto, MD32

1Division of Hematology, AOU Città della Salute e della Scienza di Torino, Torino, Italy
2Department of Molecular Biotechnology and Health Sciences, Hematology Division, University of Torino, Torino, Italy
3Hematology, Department of Translational and Precision Medicine, Sapienza University, Roma, Italy
4Department of Clinical and Experimental Medicine, Hematology, University of Pisa, Pisa, Italy
5Clinical and Experimental Onco-Hematology Unit, Centro di Riferimento Oncologico, I.R.C.C.S., Aviano, Italy
6Fondazione Italiana Linfomi, Clinical Trial Office, Modena, Italy
7AIL Roma Odv, Rome, Italy
8SC Ematologia, AOU Città della Salute e della Scienza, Torino, Italy
9SC Ematologia, Fondazione IRCCS Istituto Nazionale Tumori, Milano, Italy
10Clinica Ematologica, Centro Trapianti e Terapie Cellulari "Carlo Melzi", Azienda Sanitaria Universitaria Integrata di Udine, Udine, Italy
11Department of Molecular Medicine, University of Pavia, Pavia, Italy
12IRCCS Ospedale Policlinico San Martino, Genoa, Italy
13Division of Hematology, Department of Translational Medicine, University of Eastern Piedmont, Novara, Italy
14Division of Hematology, ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy, Milano, IT-MI, Italy
15Dipartimento di Medicina Traslazionale Università del Piemonte Orientale e SCDU Ematologia, Az Ospedaliera Santi Antonio e Biagio e Cesare Arrigo, Alessandria, Italy
16IRCCS Istituto Romagnolo per lo studio dei Tumori (IRST) “Dino Amadori”, Meldola, Italy
17Ospedale degli Infermi di Rimini - U.O. di Ematologia, Rimini, ITA
18Hematology, University Hospital "Ospedale di Circolo e Fondazione Macchi" - ASST Sette Laghi, Varese, Italy
19Fondazione Irccs San Gerardo, SC di Ematologia, Monza, Italy
20Hematology Unit, Azienda C. Panico, Tricase, Italy
21A.O.U. Policlinico "G. Rodolico-S.Marco", Catania, U.O.C. Ematologia, Catania, Italy
22UO Ematologia, Ospedale Guglielmo da Saliceto, Piacenza, Italy
23EMATOLOGIA, ASL SALERNO, PRESIDIO OSPEDALIERO TORTORA PAGANI, Pagani, ITA
24Dipartimento di Scienze Mediche e Chirurgiche Materno-Infantili e dell'Adulto, Università di Modena e Reggio Emilia, Modena, Italy., Modena, Italy
25SC Ematologia, AO S. Croce e Carle, Cuneo, Italy
26SSD Ematologia, Nuovo Ospedale degli Infermi, Biella, Italy
27Department of Precision and Regenerative Medicine and Ionian Area, Unit of Hematology with Transplantation, Bari, Italy
28UOC di Ematologia, Dipartimento Oncoematologico, Azienda Ospedaliera Papardo, Messina, Messina, Italy
29Lymphoma Unit, Division of Hematology, ASST Spedali Civili di Brescia, Brescia, Italy
30Hematology, Azienda Unità Sanitaria Locale IRCCS of Reggio Emilia, Reggio Emilia, Italy
31Surgical, Medical and Dental Department of Morphological Sciences Related to Transplant, Oncology and Regenerative Medicine, University of Modena and Reggio Emilia, Reggio Emilia, Italy
32Department of Translational Medicine, Università del Piemonte Orientale ed SCDU Ematologia AOU SS Antonio e Biagio e Cesare Arrigo, Alessandria, Piedmont, Italy

4:45 PM

Lorenzo Falchi, MD1, Michelle Okwali, MPH1*, Alexandra Ferreira Lopes, BS2*, Paul A. Hamlin, MD1, Jennifer Kimberly Lue, MD1, Paola Ghione, MD1, Colette Owens, MD1, Pallawi Torka, MD2, Anita Kumar, MD1, Raphael Steiner, MD1*, Zachary D. Epstein-Peterson, MD1, Maria Lia Palomba, MD1, Robert Stuver, MD1, Ariela Noy, MD3, Anastasia Martinova, BSN, RN4*, Lauren Wood, MSN, RN, AGCNS-BC, OCN4*, Clare Grieve, MPH2*, Walter Ramos Amador, MPH, MS2*, Santosha A. Vardhana, MD, PhD5, Andrew D. Zelenetz, MD, PhD1, Lori A. Leslie, MD6, Joseph L. Roswarski, MD7, Kieron Dunleavy, MD8*, Andre Goy, MD, MS9 and Gilles Salles, MD, PhD1

1Lymphoma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY
2Memorial Sloan Kettering Cancer Center, New York, NY
3Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY
4Memorial Sloan Kettering Cancer Center, New York
5Lymphoma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York
6Lymphoma Division, John Theurer Cancer Center, Hackensack Meridian School of Medicine, Hackensack, NJ
7Hematologic Malignancies Department, Medstar Georgetown University Hospital, Washington, DC
8Medstar Georgetown University Hospital, Washington, DC
9Lymphoma Division, John Theurer Cancer Center, Hackensack Meridian Health, Hackensack, NJ

5:00 PM

Jing-Zhou Hou, MD, PhD1, Ranjit Nair, MD2, Ryan Jacobs3, Tae Min Kim, MD, PhD4*, Seok-Goo Cho5*, Dai Maruyama, MD, PhD6, Sumana Devata, MD7, Yazeed Sawalha, MD8, Dok Hyun Yoon, MD, PhD9, Constantine S. Tam, MD, MBBS10, Koji Izutsu, MD, PhD11, Matthew Matasar, MD, MS12, Don A. Stevens, MD13, Aravind Ramakrishnan, MD14, Denise Brennan15*, Xu Zhu15*, Robin Lesley, PhD16*, Yasuhiro Oki, MD16, David Sermer17* and Sameh Gaballa, MD18

1Lemieux Center for Blood Cancers, UPMC Hillman Cancer Center, Pittsburgh, PA
2The University of Texas MD Anderson Cancer Center, Houston, TX
3Atrium Health Levine Cancer Institute, Charlotte, NC
4Seoul National University Hospital, Seoul, Korea, Republic of (South)
5Seoul St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea, Republic of (South)
6Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan
7Medical College of Wisconsin, Milwaukee, WI
8The Ohio State University Comprehensive Cancer Center, Columbus, OH
9Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea, Republic of (South)
10Alfred Hospital and Monash University, Melbourne, VIC, Australia
11National Cancer Center Hospital, Tokyo, Japan
12Rutgers Cancer Institute, New Brunswick, NJ
13Norton Cancer Institute, Norton Health Care, Louisville, KY
14Sarah Cannon Transplant and Cellular Therapy, St. David’s South Austin Medical Center, Austin, TX
15AstraZeneca, Waltham, MA
16AstraZeneca, South San Francisco, CA
17AstraZeneca, New York, NY
18H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL

5:15 PM

Lorenzo Falchi, MD1, Anna Sureda Balari, MD, PhD2, Sirpa Leppä, MD PhD3*, Joost S.P. Vermaat4, Marcel Nijland, MD, PhD5*, Jacob Haaber Christensen, MD, PhD6*, Sven de Vos, MD, PhD7*, Harald Holte, MD, PhD8, Reid W. Merryman, MD9, Pieternella Lugtenburg, MD, PhD10, Pau Abrisqueta Costa, MD, PhD11*, Kim Linton12*, Gauri Sunkersett, DO13*, Christopher Morehouse, MS14*, Andrew J. Steele, PhD14*, Jennifer Marek14*, Liwei Wang, PhD14*, Daniela Hoehn, MD, PhD14*, Martin Hutchings, MD, PhD15 and David Belada, MD, PhD16

1Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, NY
2Clinical Hematology Department, Institut Català d’Oncologia – L’Hospitalet, IDIBELL, Universitat de Barcelona, Barcelona, Spain
3University of Helsinki and Helsinki University Hospital Comprehensive Cancer Center, Helsinki, Finland
4Leiden University Medical Center, Leiden, Netherlands
5University Medical Center Groningen and University of Groningen, Groningen, Netherlands
6Odense University Hospital, Odense, Denmark
7Ronald Reagan University of California Los Angeles Medical Center, Los Angeles, CA
8Oslo University Hospital and KG Jebsen Center for B-cell Malignancies, Oslo, Norway
9Dana-Farber Cancer Institute, Boston, MA
10On behalf of the Lunenburg Lymphoma Phase I/II Consortium-HOVON/LLPC, Erasmus MC Cancer Institute, University Medical Center, Department of Hematology, Rotterdam, Netherlands
11Hospital Universitario Vall d’Hebro, Barcelona, Spain
12The Christie NHS Foundation Trust, Manchester Cancer Research Centre, and Division of Cancer Sciences, University of Manchester, Manchester, United Kingdom
13AbbVie, North Chicago, IL
14Genmab, Plainsboro, NJ
15Rigshospitalet and University of Copenhagen, Copenhagen, Denmark
164th Department of Internal Medicine – Hematology, University Hospital and Faculty of Medicine, Hradec Kralove, Czech Republic

*signifies non-member of ASH